Nuvalent
preliminary activity tumor response across heavily patient populations phase pete a of with alk resistance mutation i including all dose levels best evaluable metastases any single compound all at doses alk ala chiral rate criteria in solid version tyrosine kinase inhibitor of allelic configuration by central pound mutations with evidence of allelic configuration without post radiographic assessment includes patients with on three patients source lin no | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
19 of 41
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preliminary activity tumor response across heavily patient populations phase alk all dose levels best response history of evaluable metastases any with alk resistance mutation single compound i prior alk including all a no a at doses data cut off mania with alk or central nervous system not evaluable objective rate tyrosine kinase inhibitor source lin | Nuvalent
Investor Presentation
February 2024
preliminary activity tumor response across heavily patient populations patients with alk all dose levels best phase all response evaluable history of metastases with alk resistance mutation any single compound prior alk including all a at doses if data cut evaluable patients with alk generation a or central system not evaluable objective rate alt inhibitor treatment source lin i no | Nuvalent
Investor Presentation
January 2024
preliminary activity tumor response across heavily patient populations phase pete a of with alk resistance mutation i including all dose levels best evaluable metastases any single compound all at doses alk ala chiral rate criteria in solid version tyrosine kinase inhibitor of allelic configuration by central pound mutations with evidence of allelic configuration without post radiographic assessment includes patients with on three patients source lin no | Nuvalent
Investor Presentation
November 2023
preliminary activity induced tumor response across heavily patient populations | Nuvalent
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights